Hospices Civils De Lyon
- Address
- lock Available on a paid plan
Hemic and Lymphatic Diseases
The research program at Hospices Civils De Lyon concentrates on blood‑related and lymphatic disorders in children and young adults, testing innovative immunotherapies and targeted agents to enhance remission rates and long‑term survival.
- Classical Hodgkin lymphoma in children and young adults
- Relapsed/Refractory Aggressive Mature B-cell Neoplasms
- Pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia
Trials aim to evaluate safety, pharmacokinetics, and objective response, offering new therapeutic options for patients who have exhausted standard treatments.
Immune System Diseases
Focused investigations address immune‑mediated complications of transplantation, including the prevention and treatment of acute graft‑versus‑host disease through advanced antibody preparations and novel small molecules.
- Steroid refractory Acute Graft versus host Disease
- Pediatric and adult patients undergoing HSC allograft procedures with Thymoglobulin® packaging
The studies characterize the pharmacokinetic profile of Thymoglobulin® and compare the efficacy of investigational agents such as MC0518 against best available therapy, seeking safer graft outcomes.
Neoplasms
A broad oncology portfolio explores solid and hematologic cancers, integrating checkpoint inhibition and bispecific antibodies to improve response in hard‑to‑treat pediatric malignancies.
- Classical Hodgkin lymphoma in children and young adults
- Relapsed/Refractory Aggressive Mature B-cell Neoplasms
- Pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia
Research evaluates the safety and activity of agents like pembrolizumab and epcoritamab, aiming to establish new standards of care for patients with resistant disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospices Civils De Lyon
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Pharmacokinetics of anti-lymphocyte serum in the prevention of GvHD in children and adults receiving allogeneic hematopoietic stem cell transplantation - PHASAL-GA Study | Hospices Civils De Lyon | Phase III | Not Recruiting | Jul 2023 | Nov 2025 |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anti-T Lymphocyte Immunoglobulin For Human Use, Rabbit | 1 | Unknown | 2023-11-13 | 2023-11-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.